
Current Price | $10.71 | Mkt Cap | $2.0B |
---|---|---|---|
Open | $10.80 | P/E Ratio | 0.00 |
Prev. Close | $10.78 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $10.66 - $10.98 | Volume | 774,887 |
52-Wk Range | $7.61 - $19.99 | Avg. Daily Vol. | 2,925,984 |
A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
Current Price | $10.71 | Mkt Cap | $2.0B |
---|---|---|---|
Open | $10.80 | P/E Ratio | 0.00 |
Prev. Close | $10.78 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $10.66 - $10.98 | Volume | 774,887 |
52-Wk Range | $7.61 - $19.99 | Avg. Daily Vol. | 2,925,984 |
The best Bull and Bear pitches based on recency and number of recommendations.
Already profitable; growing; good pipeline
As I predicted, BioCryst still had a little life left which allowed me to escape my green thumb and flip turn into a red one. 33% jump today, and all because of this:BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary… More
Read the most recent pitches from players about BCRX.
Recs
Already profitable; growing; good pipeline
Recs
COVID-19 biotech should continue to grow with oral delivery system of vaccine
Recs
Expecting positive sales of over $500 on Berotralstat approval. Plus early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases plus patient dosing underway in galidesivir trial in COVID-19 patients in Brazil. All sounds quite positive and worth a flyer.
Find the members with the highest scoring picks in BCRX.
Chemnerd (38.35) Score: +564.96
The Score Leader is the player with the highest score across all their picks in BCRX.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
cozynite | 44.84 | 3/14/2013 |
![]() |
5Y | $1.31 | +714.50% | +159.16% | +555.34 | 0 Comment | |
MrTwo94 | 91.71 | 11/8/2012 |
![]() |
1Y | $1.37 | +678.83% | +190.71% | +488.12 | 0 Comment | |
jgrnot | 33.92 | 12/4/2012 |
![]() |
5Y | $1.41 | +656.79% | +187.38% | +469.41 | 0 Comment | |
Sytes | < 20 | 5/29/2013 |
![]() |
3Y | $1.60 | +566.88% | +145.54% | +421.33 | 1 Comment | |
bearonwallstreet | 67.77 | 5/16/2013 |
![]() |
5Y | $1.70 | +527.65% | +145.01% | +382.64 | 0 Comment | |
warrenout3 | 35.79 | 12/3/2012 |
![]() |
5Y | $1.63 | +554.60% | +184.44% | +370.16 | 0 Comment | |
portefeuille2 | 98.58 | 2/16/2016 |
![]() |
5Y | $1.87 | +470.59% | +114.14% | +356.45 | 0 Comment | |
Bigsef77 | 62.26 |
|
![]() |
5Y | $1.89 | +464.55% | +116.59% | +347.96 | 0 Comment | |
portefeuille | 98.01 |
|
![]() |
NS | $1.92 | +456.02% | +116.57% | +339.45 | 0 Comment | |
Roger55125 | 26.92 | 4/24/2013 |
![]() |
5Y | $1.80 | +492.78% | +157.35% | +335.42 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.